REVBW

Revelation Biosciences Inc. a clinical stage biopharmaceutical company focuses on the development of immunologic-based therapeutics and diagnostics for the prevention and treatment of disease. The company's lead therapeutic candidate is REVTx-99 an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2 comprising its variants influenza A and B parainfluenza rhinovirus and RSV as well as is being developed for other indications comprising allergic rhinitis and chronic nasal congestion. It also develops REVTx-200 an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for immunity; and REVDx-501 a rapid home use diagnostic to detect respiratory viral infection. The company was founded in 2019 and is based in New York New York.